Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients
The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of fibrotic tissue...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257121000432 |
| _version_ | 1819098019642998784 |
|---|---|
| author | Antonio Vitiello Francesco Ferrara |
| author_facet | Antonio Vitiello Francesco Ferrara |
| author_sort | Antonio Vitiello |
| collection | DOAJ |
| description | The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of fibrotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection. |
| first_indexed | 2024-12-22T00:24:20Z |
| format | Article |
| id | doaj.art-5aa7eee3af8b44bb82db77c6a780829b |
| institution | Directory Open Access Journal |
| issn | 2590-2571 |
| language | English |
| last_indexed | 2024-12-22T00:24:20Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Pharmacology and Drug Discovery |
| spelling | doaj.art-5aa7eee3af8b44bb82db77c6a780829b2022-12-21T18:45:05ZengElsevierCurrent Research in Pharmacology and Drug Discovery2590-25712021-01-012100056Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patientsAntonio Vitiello0Francesco Ferrara1Clinical Pharmacologist, Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy; Corresponding author.Hospital Pharmacist Manager, Pharmaceutical Department, Asl Napoli 3 Sud, Dell'amicizia Street 22, 80035, Nola, Naples, Italy; Corresponding author.The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of fibrotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection.http://www.sciencedirect.com/science/article/pii/S2590257121000432FibroticPulmonaryCovid-19PharmacologyPneumonia |
| spellingShingle | Antonio Vitiello Francesco Ferrara Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients Current Research in Pharmacology and Drug Discovery Fibrotic Pulmonary Covid-19 Pharmacology Pneumonia |
| title | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
| title_full | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
| title_fullStr | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
| title_full_unstemmed | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
| title_short | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
| title_sort | physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in covid 19 patients |
| topic | Fibrotic Pulmonary Covid-19 Pharmacology Pneumonia |
| url | http://www.sciencedirect.com/science/article/pii/S2590257121000432 |
| work_keys_str_mv | AT antoniovitiello physiopathologyandprospectivesfortherapeutictreatmentofpulmonaryfibroticstateincovid19patients AT francescoferrara physiopathologyandprospectivesfortherapeutictreatmentofpulmonaryfibroticstateincovid19patients |